v3.26.1
Business Segment Information
 6 Months Ended
Apr. 30, 2026
Segment Reporting [Abstract]  
Business Segment Information
Note 10. Business Segment Information
The Company discloses information about its operating segments, which were established based on the way that our Chief Operating Decision Maker (CODM) organizes segments within the Company for making operating decisions and assessing financial performance. Our CODM is our Chief Executive Officer. The Company's two operating segments are described below.
•CooperVision. Competes in the worldwide contact lens market by developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics.
•CooperSurgical. Competes in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception.
The CODM uses operating income (loss), as presented in our financial reports, as the primary measure of segment profitability to assess the performance of the segments and make decisions on resource allocation across segments. The CODM evaluates segment operating income (loss) on a quarterly basis by comparing actual results to forecasted amounts and historical performance. These evaluations, supported by discussions with the leadership team responsible for managing the operations of each reportable segment, are used to assess segment results, monitor operating trends, and support decisions regarding the allocation of resources and consideration of investment opportunities. The Company does not allocate costs from corporate functions to segment operating income (loss). The Company uses the same accounting policies to generate segment results as it does for consolidated results.
The following tables present revenue and other financial information by reportable segment:
Segment information:
Periods Ended April 30,Three MonthsSix Months
(In millions)2026202520262025
CooperVision net sales by category:
Toric and multifocal$364.9 $328.4 $716.1 $647.8 
Sphere, other358.6 341.2 702.5 667.9 
Total CooperVision net sales$723.5 $669.6 $1,418.6 $1,315.7 
CooperSurgical net sales by category:
Office and surgical$214.2 $205.8 $416.6 $404.7 
Fertility143.8 126.9 270.4 246.6 
Total CooperSurgical net sales358.0 332.7 687.0 651.3 
Total net sales$1,081.5 $1,002.3 $2,105.6 $1,967.0 
(In millions)CooperVisionCooperSurgical
Corporate (1)
Consolidated
Three Months Ended April 30, 2026
Net sales$723.5 $358.0 $— $1,081.5 
Cost of sales229.4 116.7 — 346.1 
Selling, general and administrative expense252.2 402.4 21.6 676.2 
Research and development expense22.1 20.4 — 42.5 
Amortization expense4.2 43.5 — 47.7 
Operating income (loss)$215.6 $(225.0)$(21.6)$(31.0)
Interest expense20.9 
Other (income) expense, net
(3.5)
Income (loss) before income taxes
$(48.4)
Depreciation expense$41.3 $6.5 $— $47.8 
Capital expenditures$76.6 $9.8 $— $86.4 
As of April 30, 2026
Identifiable assets$7,626.0 $4,616.0 $240.3 $12,482.3 
Three Months Ended April 30, 2025
Net sales$669.6 $332.7 $— $1,002.3 
Cost of sales215.6 107.6 — 323.2 
Selling, general and administrative expense236.9 136.8 25.3 399.0 
Research and development expense25.6 19.9 — 45.5 
Amortization expense5.1 44.7 — 49.8 
Operating income (loss)$186.4 $23.7 $(25.3)$184.8 
Interest expense24.2 
Other (income) expense, net16.1 
Income (loss) before income taxes$144.5 
Depreciation expense$37.1 $5.9 $— $43.0 
Capital expenditures$69.4 $8.7 $— $78.1 
As of October 31, 2025
Identifiable assets$7,604.4 $4,619.3 $171.1 $12,394.8 
(1) Corporate SGA expenses are not allocated to the segments.
(In millions)CooperVisionCooperSurgical
Corporate (1)
Consolidated
Six Months Ended April 30, 2026
Net sales$1,418.6 $687.0 $— $2,105.6 
Cost of sales450.2 224.8 675.0 
Selling, general and administrative expense489.8 530.8 45.8 1,066.4 
Research and development expense44.5 42.3 86.8 
Amortization expense8.3 87.3 95.6 
Operating income (loss)$425.8 $(198.2)$(45.8)$181.8 
Interest expense43.3 
Other (income) expense, net
(5.3)
Income (loss) before income taxes
$143.8 
Depreciation expense$82.4 $13.0 $— $95.4 
Capital expenditures$170.8 $17.8 $— $188.6 
Six Months Ended April 30, 2025
Net sales$1,315.7 $651.3 $— $1,967.0 
Cost of sales420.6 207.1 — 627.7 
Selling, general and administrative expense466.8 272.7 47.4 786.9 
Research and development expense48.1 38.1 — 86.2 
Amortization expense9.9 89.5 — 99.4 
Operating income (loss)$370.3 $43.9 $(47.4)$366.8 
Interest expense50.2 
Other (income) expense, net
18.8 
Income (loss) before income taxes$297.8 
Depreciation expense$72.4 $12.0 $— $84.4 
Capital expenditures$145.0 $22.5 $— $167.5 
(1) Corporate SGA expenses are not allocated to the segments.
Geographic information:
Periods Ended April 30,Three MonthsSix Months
(In millions)2026202520262025
Net sales to unaffiliated customers by country of domicile:
United States$547.8 $515.2 $1,061.7 $1,011.6 
Europe341.6 291.9 668.0 579.4 
Rest of world192.1 195.2 375.9 376.0 
Total$1,081.5 $1,002.3 $2,105.6 $1,967.0 
(In millions)April 30, 2026October 31, 2025
Net property, plant and equipment by country of domicile:
United States$1,429.1 $1,389.4 
Europe445.7 429.1 
Rest of world257.4 263.5 
Total$2,132.2 $2,082.0